Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis
Authors:
Open Access
- 22 December 2021
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (4) , 623-645
Abstract
Purpose: This study aimed to estimate the prevalence, contributory factors, and severity of medication errors associated with direct acting oral anticoagulants (DOACs). Methods: A systematic review and meta-analysis were undertaken by searching 11 databases including Medline, Embase, and CINHAL between January 2008 and September 2020. The pooled prevalence of errors and predictive intervals were estimated using random-effects models using Stata software. Data related to error causation were synthesised according to Reason’s accident causation model. Results: From the 5205 titles screened, 32 studies were included which were mostly based in hospitals and included DOAC treatment for thromboembolism and atrial fibrillation. The proportion of study population who experienced either prescription, administration, or dispensing error ranged from 5.3 to 37.3%. The pooled percentage of patients experiencing prescribing error was 20% (95% CI 15–25%; I2 = 96%; 95% PrI 4–43%). Prescribing error constituted the majority of all error types with a pooled estimate of 78% (95%CI 73–82%; I2 = 0) of all errors. The common reported causes were active failures including wrong drug, and dose for the indication. Mistakes such as non-consideration of renal function, and error-provoking conditions such as lack of knowledge were common contributing factors. Adverse events such as potentially fatal intracranial haemorrhage or patient deaths were linked to the errors but causality assessments were often missing. Conclusions: Despite their favourable safety profile, DOAC medication errors are common. There is a need to promote multidisciplinary working, guideline-adherence, training, and education of healthcare professionals, and the use of theory-based and technology-facilitated interventions to minimise errors and maximise the benefits of DOACs usage in all settings. Protocol: A protocol developed as per PRISMA-P guideline is registered under PROSPERO ID = CRD42019122996Keywords
This publication has 40 references indexed in Scilit:
- Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospitalJournal of Clinical Pharmacy and Therapeutics, 2015
- An observational case series of dabigatran and rivaroxaban exposures reported to a poison control systemThe American Journal of Emergency Medicine, 2014
- Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugsEuropean Journal of Clinical Pharmacology, 2013
- Exploratory Evaluation of Medication Classes Most Commonly Involved in Nursing Home ErrorsJournal of the American Medical Directors Association, 2013
- Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinicPharmacy Practice, 2013
- Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxabanClinical Research in Cardiology, 2013
- Drug use evaluation of dabigatran in a tertiary care hospital in United Arab EmiratesEuropean Journal of Hospital Pharmacy, 2012
- Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and HaemostasisJournal of Thrombosis and Haemostasis, 2012
- Anticoagulation-associated Adverse Drug EventsThe American Journal of Medicine, 2011
- A Re-Evaluation of Random-Effects Meta-AnalysisJournal of the Royal Statistical Society Series A: Statistics in Society, 2008